McDiarmid

Altus Group Nominates Jim Hannon and Will Brennan to its Board of Directors

Retrieved on: 
星期三, 二月 28, 2024
Collection, Corporate governance, Intelligence, Risk management, CRE, TSX, Altus Group, Growth, MBA, CFA, Human resources, Compensated emancipation, University, Partner, Committee, AGM, Harvard Business School, Economics, McDiarmid, Management

“Our strategic growth plan includes expanding Altus Group’s asset performance and risk management solutions to help clients drive superior performance through advanced analytics.

Key Points: 
  • “Our strategic growth plan includes expanding Altus Group’s asset performance and risk management solutions to help clients drive superior performance through advanced analytics.
  • Their addition to the Board is an important step in our ongoing board refreshment process.”
    Will Brennan is the Managing Partner of Long Path Partners, an investment firm that he founded in 2018, and a long-standing shareholder of Altus Group.
  • He brings a unique investor perspective to the Board with a deep understanding of Altus Group’s operations and market opportunity.
  • Both directors have made lasting contributions to Altus Group’s corporate governance initiatives and continual efforts to drive shareholder value.

EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options

Retrieved on: 
星期一, 十一月 27, 2023
Drug resistance, McDiarmid, Quality of life, Immunotherapy, Survival, Heel, Immune system, Human body weight, Lead, Neoplasm, Clinical trial, Cancer, Rated R, EDV, Pancreatic cancer, Conditional sentence, PDAC, Toxicity, Weight gain, Optimism, Patient, Therapy, Pharmaceutical industry

The trial results highlight a significant advance in the treatment landscape for PDAC:

Key Points: 
  • The trial results highlight a significant advance in the treatment landscape for PDAC:
    Unprecedented Survival Rates.
  • The trial demonstrated a substantial increase in median overall survival for patients, with 88% of participants surpassing at least double the historical survival rates.
  • Remarkably, more than 80% of patients receiving the EDV treatment either maintained or experienced weight gain.
  • Joint-CEO and Director of EnGeneIC, Dr Jennifer MacDiarmid said, “We are very excited about the results of our Carolyn Trial.

EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal

Retrieved on: 
星期二, 一月 31, 2023
Thought, Antibody, Mouse, Disease, Joint, Human, COVID-19, Ethics, Cancer, Rheumatoid arthritis, Big Pharma, Vaccine, EDV, Hospital, Omicron, Therapy, Edve, Vaccination, COVID, Patient, Volunteering, Engen, Germany, Falls, Volatile organic compound, McDiarmid, Frontiers, Temperature, Steroid, Immunology, Health care

EnGeneIC, an Australian clinical stage biotechnology company, has developed therapeutics for end stage patients with low survival cancers based on its revolutionary and world first EDV™ nanocell cyto-immunotherapy platform (EDV; EnGeneIC Dream Vector).

Key Points: 
  • EnGeneIC, an Australian clinical stage biotechnology company, has developed therapeutics for end stage patients with low survival cancers based on its revolutionary and world first EDV™ nanocell cyto-immunotherapy platform (EDV; EnGeneIC Dream Vector).
  • More recently, the company discovered that the same EDV nanocell can deliver viral antigens, resulting in its novel COVID-EDV vaccine.
  • EnGeneIC is currently conducting trials of its groundbreaking vaccine in Sydney and Melbourne and has vaccinated 80 volunteers.
  • Many of these people are too stressed and concerned about the consequences of getting COVID – we strongly believe that we can help.

Wickaninnish Inn Launches “A Journey to Nature’s Edge” Podcast

Retrieved on: 
星期二, 十一月 1, 2022
Storm, History, GLOBE, Inn, Family, Adventure, Parent, Hotel, McDiarmid, BC

TOFINO, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Wickaninnish Inn today launched A Journey to Natures Edge a podcast that shares the history of the McDiarmid family, the founders of the Wickaninnish Inn, and their friends rugged west coast adventures.

Key Points: 
  • TOFINO, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Wickaninnish Inn today launched A Journey to Natures Edge a podcast that shares the history of the McDiarmid family, the founders of the Wickaninnish Inn, and their friends rugged west coast adventures.
  • A Journey to Natures Edge podcast gives a glimpse of the days when Tofino was a remote fishing and logging village, long before it became the vibrant tourist destination it is today.
  • A Journey to Natures Edge launches at the beginning of Tofinos Winter Storm Watching Season, an increasingly popular time of year for visitors, first promoted by Wickaninnish Inn.
  • Hosted by Cameron Dennison of local Tofino broadcaster, Tuff City Radio The Journey to Natures Edge Podcast begins with three episodes:

Xander Resources Acquires 100 Claims West of CNC's Crawford Project

Retrieved on: 
星期五, 十月 21, 2022
Lithium, News, Metal, National instrument, FSX, VWAP, Vendor, Eldorado Gold, McDiarmid, Val-d'Or, Agreement, Multimedia, Acquisition, Company, Accident, Mining, Industry, TSX Venture Exchange, Legislation, Incentive stock option, Nature, Mergers and acquisitions, Date, Geotechnical engineering, CNC, Maslow CNC, Uranium, Security (finance), Life insurance, Cryptocurrency, Risk management, Share (finance), BC, Exchange

VANCOUVER, BC, Oct. 21, 2022 /PRNewswire/ - Xander Resources Inc. ("Xander" or the "Company") (TSXV: XND) (OTCQB: XNDRF) (FSX: 1XI)is pleased to announce that it has entered into an option agreement (the "Option") to acquire (the "Acquisition") 100% interest in certain 100 mineral claims (the "Claims" and the "Property") located in Timmins, Ontario.

Key Points: 
  • VANCOUVER, BC, Oct. 21, 2022 /PRNewswire/ - Xander Resources Inc. ("Xander" or the "Company") (TSXV: XND) (OTCQB: XNDRF) (FSX: 1XI)is pleased to announce that it has entered into an option agreement (the "Option") to acquire (the "Acquisition") 100% interest in certain 100 mineral claims (the "Claims" and the "Property") located in Timmins, Ontario.
  • The property consists of 100 separate mineral claim blocks comprising over 21 square kilometres that are located contiguous to the west of the Company's existing Timmins North claims.
  • Deepak Varshney, Xander CEO, said, "We are very pleased to have been able to add these claims to our portfolio.
  • Xander Resources Inc. is a Canadian mineral acquisition and exploration company based in Vancouver, BC, Canada focused on developing accretive gold and battery metal properties within Canada.

EnGeneIC’s second generation COVID-19 vaccine protects against all variants

Retrieved on: 
星期二, 六月 28, 2022
John Engen, Patient, Antibody, Sydney Adventist Hospital, Chief executive officer, GLOBE, COVID-19, Population, Cancer, Omicron, BA2, Disease, McDiarmid, Immune system, Infection, EDV, Sirna, Toxicity, Temperature, Vaccine, Safety, Immunity, Volunteering, Diabetes, Rheumatoid arthritis, Pharmaceutical industry, Ethics

SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The worlds first COVID-19 vaccine to offer immunity against all variants is one step closer.

Key Points: 
  • SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The worlds first COVID-19 vaccine to offer immunity against all variants is one step closer.
  • Clinical trials have shown the novel vaccine works by stimulating a completely different immune pathway from other vaccines, producing high affinity antibodies that neutralise all COVID-19 variants.
  • Australian Biopharma company EnGeneIC is currently conducting trials of its groundbreaking vaccine in Sydney and Melbourne.
  • Were very excited by these results and to be part of EnGeneICs anti-COVID-19 vaccine trial, particularly in light of its being an Australian innovation, he said.

Canada Nickel Announces Successful Drill Results from Recently Acquired Deloro target and Provides Corporate Update

Retrieved on: 
星期一, 一月 24, 2022
The Company, CNC, Mining, CEO, McDiarmid, Nickel, Company, Nesbitt, Environment, Engineering, Road, Mahaffy, Dargavel

First hole in recently acquired properties intersects 480 metres of dunite at Deloro using a sixth drill rig acquired at start of year.

Key Points: 
  • First hole in recently acquired properties intersects 480 metres of dunite at Deloro using a sixth drill rig acquired at start of year.
  • Announces management additions in engineering and environment to support Company efforts to advance Crawford through feasibility and subsequent steps towards development.
  • TORONTO, Jan. 24, 2022 /PRNewswire/ -Canada Nickel Company Inc.("Canada Nickel" or the "Company") (TSXV: CNC) (OTCQX: CNIKF) today announced assay results from its Mahaffy, Dargavel, Kingsmill, and MacDiarmid properties, and provided an update on drilling and corporate activities.
  • Only specific non-consecutive intervals were assayed, for example, FY02-02 reported 0.42% nickel over a core length of 4.2 metres.

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment

Retrieved on: 
星期二, 十一月 30, 2021
Patient, Pancreatic cancer, Los Angeles, Cancer, McDiarmid, Technology, EDV, Temperature, Weeping Angel, IIA, Protein-bound paclitaxel, Clinical trial, Therapy, COVID-19, Phase II, Sirna, GLOBE, Globe, Antibody, III, FDA, Asbjørn Engen, Infection, Lists of countries and territories, Immune system, Immunotherapy, NEW, Toxicity, COVID, Brahmbhatt, Pharmaceutical industry, Vaccine

SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both a COVID-19 vaccine and cancer treatment.

Key Points: 
  • SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both a COVID-19 vaccine and cancer treatment.
  • Phase I and IIa trials in patients with advanced pancreatic cancer is underway, and the FDA recently approved another trial in the US.
  • ImmunityBios Executive Chairman is billionaire businessman, doctor and scientist, Patrick Soon-Shiong, who invented the drug Abraxane, used in the treatment of pancreatic cancer.
  • Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV in combination with its anti-cancer drugs and COVID-19 vaccine.

Canada Nickel Completes Previously Announced Property Acquisitions

Retrieved on: 
星期二, 十一月 16, 2021
Nickel, Iron, Legislation, Metal, News, Heart, TSX Venture Exchange, Property, Failure, COVID-19, Multimedia, McDiarmid, Intention, Sale, Acquisition, Carbon, Cobalt, Company, CNC, Cryptocurrency, Mining

This transaction was previously announced by Canada Nickel in a news release on April 22, 2021.

Key Points: 
  • This transaction was previously announced by Canada Nickel in a news release on April 22, 2021.
  • The principal terms of the transaction are as follows:
    Noble will transfer ownership and title to the Properties to Canada Nickel.
  • Canada Nickel will issue 3.5 million common shares of Canada Nickel to Noble as payment under this transaction.
  • Canada Nickel provides investors with leverage to nickel and cobalt in low political risk jurisdictions.